Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | ENTX |
---|---|---|
09:32 ET | 4318 | 1.66 |
09:37 ET | 375 | 1.74 |
09:42 ET | 100 | 1.7 |
09:50 ET | 1000 | 1.7207 |
10:15 ET | 500 | 1.7 |
10:18 ET | 100 | 1.71 |
10:27 ET | 100 | 1.7 |
10:40 ET | 1625 | 1.68 |
10:51 ET | 1000 | 1.68 |
11:18 ET | 100 | 1.68 |
11:38 ET | 200 | 1.68 |
11:48 ET | 200 | 1.68 |
12:03 ET | 5000 | 1.7229 |
12:06 ET | 100 | 1.68 |
12:15 ET | 100 | 1.71 |
12:44 ET | 360 | 1.715 |
12:50 ET | 250 | 1.7 |
01:00 ET | 100 | 1.68 |
01:08 ET | 100 | 1.68 |
01:11 ET | 5000 | 1.71 |
01:18 ET | 286 | 1.6875 |
01:22 ET | 100 | 1.73 |
01:27 ET | 100 | 1.6801 |
01:36 ET | 100 | 1.69 |
02:00 ET | 1000 | 1.6882 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Entera Bio Ltd | 62.6M | -6.4x | --- |
Maia Biotechnology Inc | 62.9M | -1.6x | --- |
RetinalGenix Technologies Inc | 63.0M | -15.3x | --- |
Mural Oncology PLC | 61.7M | -0.3x | --- |
enVVeno Medical Corp | 63.9M | -2.6x | --- |
RAPT Therapeutics Inc | 61.1M | -0.6x | --- |
Entera Bio Ltd is an Israel-based clinical-stage biopharmaceutical company focused on the development and commercialization of orally delivered large molecule therapeutics for use in areas with unmet medical need and where adoption of injectable therapies is limited due to cost, convenience and compliance challenges for patients. The Company developed a platform that enables the oral delivery of injectable proteins and large molecules. Entera Bio candidates are EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism. Both EB613 and EB612 are oral formulations of human parathyroid hormone (1-34), or Parathormon (PTH). The products are administered via injection.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $62.6M |
---|---|
Revenue (TTM) | $57.0K |
Shares Outstanding | 36.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.57 |
EPS | $-0.26 |
Book Value | $0.29 |
P/E Ratio | -6.4x |
Price/Sales (TTM) | 1,098.5 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -15,045.61% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.